Blackstone Life Sciences funds R&D for Alnylam

Susan Barreto Susan BarretoAugust 17, 2020
1 minute read
Blackstone Life Sciences funds R&D for Alnylam
Public Domain Images/Pexels

Blackstone and Alnylam Pharmaceuticals closed the R&D funding component of the companies’ Continue Reading With a Free Trial

Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.

Already a subscriber? Log in.

Tags
Susan Barreto Susan BarretoAugust 17, 2020
1 minute read

Related Articles

Marathon raises $900m for asset-based lending strategy

Marathon raises $900m for asset-based lending strategy

January 26, 2021
Gauge Capital attracts $800m for third fund

Gauge Capital attracts $800m for third fund

January 26, 2021
New Mexico considering initial 2021 allocations in credit, real estate, PE

New Mexico considering initial 2021 allocations in credit, real estate, PE

January 26, 2021
Coller Capital raises $9bn for eighth fund

Coller Capital raises $9bn for eighth fund

January 26, 2021
Back to top button

Get our daily news digest
in your inbox

Our FREE mailing list brings you daily alts intel.

Thank you for subscribing.

Something went wrong.

The form collects name and email so that we can add you to our newsletter list for project updates. Checkout our privacy policy for the full story on how we protect and manage your submitted data!

Terms and Conditions - Privacy Policy